Trial Profile
A Randomised controlled Phase II trial of the pharmacodynamic effects of the heat shock protein 90 (Hsp90) inhibitor AUY922 in high-risk, localised prostate cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Luminespib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 02 Aug 2014 New trial record